期刊
CURRENT ALLERGY AND ASTHMA REPORTS
卷 16, 期 6, 页码 -出版社
CURRENT MEDICINE GROUP
DOI: 10.1007/s11882-016-0624-7
关键词
Autoimmune disease; Biologics; Monoclonal antibody; Primary immunodeficiency; Secondary immunodeficiency; Biologic safety
资金
- [T32-HD043021]
Recent advances in the understanding of immune dysregulation in autoimmune diseases have enabled the development of new monoclonal antibody-based drugs called biologics. Biologics have been used to target aberrant immune responses in many diseases, but patients with rheumatologic and other autoimmune diseases have benefited the most and improvements in outcomes have been significant. The use of biologics is not without hazard, however, as these agents block immune pathways adapted to protect the host. This has been borne out by increased rates of infections as well as induction of new autoimmune and hematologic adverse effects. As new drugs for the treatment of autoimmune conditions are entering the pipeline, it is incumbent on the practicing immunologist to understand the mechanism of these biologics and the implications of clinical use.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据